Rates of spontaneous mutation critically determine the genetic diversity and evolution of RNA viruses. Although these rates have been characterized in vitro and in cell culture models, they have seldom been determined in vivo for human viruses. Here, we use the intrapatient frequency of premature stop codons to quantify the HIV-1 genome-wide rate of spontaneous mutation in DNA sequences from peripheral blood mononuclear cells. This reveals an extremely high mutation rate of (4.1 ± 1.7) × 10？3 per base per cell, the highest reported for any biological entity. Sequencing of plasma-derived sequences yielded a mutation frequency 44 times lower, indicating that a large fraction of viral genomes are lethally mutated and fail to reach plasma. We show that the HIV-1 reverse transcriptase contributes only 2% of mutations, whereas 98% result from editing by host cytidine deaminases of the A3 family. Hypermutated viral sequences are less abundant in patients showing rapid disease progression compared to normal progressors, highlighting the antiviral role of A3 proteins. However, the amount of A3-mediated editing varies broadly, and we find that low-edited sequences are more abundant among rapid progressors, suggesting that suboptimal A3 activity might enhance HIV-1 genetic diversity and pathogenesis.
References
[1]
Perelson AS. Modelling viral and immune system dynamics. Nat Rev Immunol. 2002;2:28–36. pmid:11905835 doi: 10.1038/nri700
[2]
Fraser C, Lythgoe K, Leventhal GE, Shirreff G, Hollingsworth TD, Alizon S, et al. Virulence and pathogenesis of HIV-1 infection: an evolutionary perspective. Science. 2014;343:1243727. doi: 10.1126/science.1243727. pmid:24653038
[3]
Smyth RP, Davenport MP, Mak J. The origin of genetic diversity in HIV-1. Virus Res. 2012;169:415–29. doi: 10.1016/j.virusres.2012.06.015. pmid:22728444
[4]
Sanjuán R, Nebot MR, Chirico N, Mansky LM, Belshaw R. Viral mutation rates. J Virol. 2010;84:9733–48. doi: 10.1128/JVI.00694-10. pmid:20660197
[5]
Lauring AS, Frydman J, Andino R. The role of mutational robustness in RNA virus evolution. Nat Rev Microbiol. 2013;11:327–36. doi: 10.1038/nrmicro3003. pmid:23524517
[6]
Abram ME, Ferris AL, Shao W, Alvord WG, Hughes SH. Nature, position, and frequency of mutations made in a single cycle of HIV-1 replication. J Virol. 2010;84:9864–78. doi: 10.1128/JVI.00915-10. pmid:20660205
[7]
Mansky LM. Retrovirus mutation rates and their role in genetic variation. J Gen Virol. 1998;79:1337–45. pmid:9634073 doi: 10.1099/0022-1317-79-6-1337
[8]
Roberts JD, Bebenek K, Kunkel TA. The accuracy of reverse transcriptase from HIV-1. Science. 1988;242:1171–3. pmid:2460925 doi: 10.1126/science.2460925
[9]
Ji JP, Loeb LA. Fidelity of HIV-1 reverse transcriptase copying RNA in vitro. Biochemistry. 1992;31:954–8. pmid:1370910 doi: 10.1021/bi00119a002
[10]
Julias JG, Pathak VK. Deoxyribonucleoside triphosphate pool imbalances in vivo are associated with an increased retroviral mutation rate. J Virol. 1998;72:7941–9. pmid:9733832
[11]
Mansky LM, Le Rouzic E, Benichou S, Gajary LC. Influence of reverse transcriptase variants, drugs, and Vpr on human immunodeficiency virus type 1 mutant frequencies. J Virol. 2003;77:2071–80. pmid:12525642 doi: 10.1128/jvi.77.3.2071-2080.2003
[12]
Holtz CM, Mansky LM. Variation of HIV-1 mutation spectra among cell types. J Virol. 2013;87:5296–9. doi: 10.1128/JVI.03576-12. pmid:23449788
[13]
Desimmie BA, Delviks-Frankenberrry KA, Burdick RC, Qi D, Izumi T, Pathak VK. Multiple APOBEC3 restriction factors for HIV-1 and one Vif to rule them all. J Mol Biol. 2014;426:1220–45. doi: 10.1016/j.jmb.2013.10.033. pmid:24189052
[14]
Moris A, Murray S, Cardinaud S. AID and APOBECs span the gap between innate and adaptive immunity. Front Microbiol. 2014;5:534. doi: 10.3389/fmicb.2014.00534. pmid:25352838
[15]
Santa-Marta M, de Brito PM, Godinho-Santos A, Goncalves J. Host Factors and HIV-1 Replication: Clinical Evidence and Potential Therapeutic Approaches. Front Immunol. 2013;4:343. doi: 10.3389/fimmu.2013.00343. pmid:24167505
[16]
Armitage AE, Deforche K, Chang CH, Wee E, Kramer B, Welch JJ, et al. APOBEC3G-induced hypermutation of human immunodeficiency virus type-1 is typically a discrete "all or nothing" phenomenon. PLoS Genet. 2012;8:e1002550. doi: 10.1371/journal.pgen.1002550. pmid:22457633
[17]
Monajemi M, Woodworth CF, Zipperlen K, Gallant M, Grant MD, Larijani M. Positioning of APOBEC3G/F mutational hotspots in the human immunodeficiency virus genome favors reduced recognition by CD8+ T cells. PLoS ONE. 2014;9:e93428. doi: 10.1371/journal.pone.0093428. pmid:24722422
[18]
Sadler HA, Stenglein MD, Harris RS, Mansky LM. APOBEC3G contributes to HIV-1 variation through sublethal mutagenesis. J Virol. 2010;84:7396–404. doi: 10.1128/JVI.00056-10. pmid:20463080
[19]
Binka M, Ooms M, Steward M, Simon V. The activity spectrum of Vif from multiple HIV-1 subtypes against APOBEC3G, APOBEC3F, and APOBEC3H. J Virol. 2012;86:49–59. doi: 10.1128/JVI.06082-11. pmid:22013041
[20]
Ooms M, Brayton B, Letko M, Maio SM, Pilcher CD, Hecht FM, et al. HIV-1 Vif adaptation to human APOBEC3H haplotypes. Cell Host Microbe. 2013;14:411–21. doi: 10.1016/j.chom.2013.09.006. pmid:24139399
[21]
Refsland EW, Hultquist JF, Luengas EM, Ikeda T, Shaban NM, Law EK, et al. Natural polymorphisms in human APOBEC3H and HIV-1 Vif combine in primary T lymphocytes to affect viral G-to-A mutation levels and infectivity. PLoS Genet. 2014;10:e1004761. doi: 10.1371/journal.pgen.1004761. pmid:25411794
[22]
Wang X, Abudu A, Son S, Dang Y, Venta PJ, Zheng YH. Analysis of human APOBEC3H haplotypes and anti-human immunodeficiency virus type 1 activity. J Virol. 2011;85:3142–52. doi: 10.1128/JVI.02049-10. pmid:21270145
[23]
Amoedo ND, Afonso AO, Cunha SM, Oliveira RH, Machado ES, Soares MA. Expression of APOBEC3G/3F and G-to-A hypermutation levels in HIV-1-infected children with different profiles of disease progression. PLoS ONE. 2011;6:e24118. doi: 10.1371/journal.pone.0024118. pmid:21897871
[24]
Eyzaguirre LM, Charurat M, Redfield RR, Blattner WA, Carr JK, Sajadi MM. Elevated hypermutation levels in HIV-1 natural viral suppressors. Virology. 2013;443:306–12. doi: 10.1016/j.virol.2013.05.019. pmid:23791226
[25]
Kourteva Y, De PM, Allos T, McMunn C, D'Aquila RT. APOBEC3G expression and hypermutation are inversely associated with human immunodeficiency virus type 1 (HIV-1) burden in vivo. Virology. 2012;430:1–9. doi: 10.1016/j.virol.2012.03.018. pmid:22579353
[26]
Piantadosi A, Humes D, Chohan B, McClelland RS, Overbaugh J. Analysis of the percentage of human immunodeficiency virus type 1 sequences that are hypermutated and markers of disease progression in a longitudinal cohort, including one individual with a partially defective Vif. J Virol. 2009;83:7805–14. doi: 10.1128/JVI.00280-09. pmid:19494014
[27]
Gago S, Elena SF, Flores R, Sanjuán R. Extremely high mutation rate of a hammerhead viroid. Science. 2009;323:1308. doi: 10.1126/science.1169202. pmid:19265013
[28]
Kieffer TL, Kwon P, Nettles RE, Han Y, Ray SC, Siliciano RF. G→A hypermutation in protease and reverse transcriptase regions of human immunodeficiency virus type 1 residing in resting CD4+ T cells in vivo. J Virol. 2005;79:1975–80. pmid:15650227 doi: 10.1128/jvi.79.3.1975-1980.2005
[29]
Russell RA, Moore MD, Hu WS, Pathak VK. APOBEC3G induces a hypermutation gradient: purifying selection at multiple steps during HIV-1 replication results in levels of G-to-A mutations that are high in DNA, intermediate in cellular viral RNA, and low in virion RNA. Retrovirology. 2009;6:16. doi: 10.1186/1742-4690-6-16. pmid:19216784
[30]
Keele BF, Giorgi EE, Salazar-Gonzalez JF, Decker JM, Pham KT, Salazar MG, et al. Identification and characterization of transmitted and early founder virus envelopes in primary HIV-1 infection. Proc Natl Acad Sci USA. 2008;105:7552–7. doi: 10.1073/pnas.0802203105. pmid:18490657
[31]
Kraytsberg Y, Khrapko K. Single-molecule PCR: an artifact-free PCR approach for the analysis of somatic mutations. Expert Rev Mol Diagn. 2005;5:809–15. pmid:16149882 doi: 10.1586/14737159.5.5.809
[32]
Palmer S, Kearney M, Maldarelli F, Halvas EK, Bixby CJ, Bazmi H, et al. Multiple, linked human immunodeficiency virus type 1 drug resistance mutations in treatment-experienced patients are missed by standard genotype analysis. J Clin Microbiol. 2005;43:406–13. pmid:15635002 doi: 10.1128/jcm.43.1.406-413.2005
[33]
Ramachandran S, Xia GL, Ganova-Raeva LM, Nainan OV, Khudyakov Y. End-point limiting-dilution real-time PCR assay for evaluation of hepatitis C virus quasispecies in serum: performance under optimal and suboptimal conditions. J Virol Methods. 2008;151:217–24. doi: 10.1016/j.jviromet.2008.05.005. pmid:18571738
[34]
Salazar-Gonzalez JF, Bailes E, Pham KT, Salazar MG, Guffey MB, Keele BF, et al. Deciphering human immunodeficiency virus type 1 transmission and early envelope diversification by single-genome amplification and sequencing. J Virol. 2008;82:3952–70. doi: 10.1128/JVI.02660-07. pmid:18256145
[35]
Mansky LM, Temin HM. Lower in vivo mutation rate of human immunodeficiency virus type 1 than that predicted from the fidelity of purified reverse transcriptase. J Virol. 1995;69:5087–94. pmid:7541846
[36]
Menéndez-Arias L. Mutation rates and intrinsic fidelity of retroviral reverse transcriptases. Viruses. 2009;1:1137–65. doi: 10.3390/v1031137. pmid:21994586
[37]
Armitage AE, Katzourakis A, de OT, Welch JJ, Belshaw R, Bishop KN, et al. Conserved footprints of APOBEC3G on Hypermutated human immunodeficiency virus type 1 and human endogenous retrovirus HERV-K(HML2) sequences. J Virol. 2008;82:8743–61. doi: 10.1128/JVI.00584-08. pmid:18562517
[38]
Kijak GH, Janini LM, Tovanabutra S, Sanders-Buell E, Arroyo MA, Robb ML, et al. Variable contexts and levels of hypermutation in HIV-1 proviral genomes recovered from primary peripheral blood mononuclear cells. Virology. 2008;376:101–11. doi: 10.1016/j.virol.2008.03.017. pmid:18436274
[39]
Langford SE, Ananworanich J, Cooper DA. Predictors of disease progression in HIV infection: a review. AIDS Res Ther. 2007;4:11. pmid:17502001 doi: 10.1186/1742-6405-4-11
[40]
Mellors JW, Rinaldo CR Jr., Gupta P, White RM, Todd JA, Kingsley LA. Prognosis in HIV-1 infection predicted by the quantity of virus in plasma. Science. 1996;272:1167–70. pmid:8638160 doi: 10.1126/science.272.5265.1167
[41]
Ulenga NK, Sarr AD, Hamel D, Sankale JL, Mboup S, Kanki PJ. The level of APOBEC3G (hA3G)-related G-to-A mutations does not correlate with viral load in HIV type 1-infected individuals. AIDS Res Hum Retroviruses. 2008;24:1285–90. doi: 10.1089/aid.2008.0072. pmid:18851679
[42]
Wang H, Lv G, Zhou X, Li Z, Liu X, Yu XF, et al. Requirement of HIV-1 Vif C-terminus for Vif-CBF-ss interaction and assembly of CUL5-containing E3 ligase. BMC Microbiol. 2014;14:290. doi: 10.1186/s12866-014-0290-7. pmid:25424878
[43]
Davenport MP, Loh L, Petravic J, Kent SJ. Rates of HIV immune escape and reversion: implications for vaccination. Trends Microbiol. 2008;16:561–6. doi: 10.1016/j.tim.2008.09.001. pmid:18964018
[44]
Korber BT, Letvin NL, Haynes BF. T-cell vaccine strategies for human immunodeficiency virus, the virus with a thousand faces. J Virol. 2009;83:8300–14. doi: 10.1128/JVI.00114-09. pmid:19439471
[45]
Vignuzzi M, Wendt E, Andino R. Engineering attenuated virus vaccines by controlling replication fidelity. Nat Med. 2008;14:154–61. doi: 10.1038/nm1726. pmid:18246077
[46]
Holmes EC. The evolution and emergence of RNA viruses. Oxford University Press; 2009.
[47]
Pepin KM, Lass S, Pulliam JR, Read AF, Lloyd-Smith JO. Identifying genetic markers of adaptation for surveillance of viral host jumps. Nat Rev Microbiol. 2010;8:802–13. doi: 10.1038/nrmicro2440. pmid:20938453
[48]
Pfeiffer JK, Kirkegaard K. Increased fidelity reduces poliovirus fitness and virulence under selective pressure in mice. PLoS Pathog. 2005;1:e11. pmid:16220146 doi: 10.1371/journal.ppat.0010011
[49]
Vignuzzi M, Stone JK, Arnold JJ, Cameron CE, Andino R. Quasispecies diversity determines pathogenesis through cooperative interactions in a viral population. Nature. 2006;439:344–8. pmid:16327776 doi: 10.1038/nature04388
[50]
Coffey LL, Beeharry Y, Borderia AV, Blanc H, Vignuzzi M. Arbovirus high fidelity variant loses fitness in mosquitoes and mice. Proc Natl Acad Sci USA. 2011;108:16038–43. doi: 10.1073/pnas.1111650108. pmid:21896755
[51]
Korboukh VK, Lee CA, Acevedo A, Vignuzzi M, Xiao Y, Arnold JJ, et al. RNA virus population diversity, an optimum for maximal fitness and virulence. J Biol Chem. 2014;289:29531–44. doi: 10.1074/jbc.M114.592303. pmid:25213864
[52]
Meng T, Kwang J. Attenuation of human enterovirus 71 high-replication-fidelity variants in AG129 mice. J Virol. 2014;88:5803–15. doi: 10.1128/JVI.00289-14. pmid:24623423
[53]
Cuevas JM, Gonzalez-Candelas F, Moya A, Sanjuán R. The effect of ribavirin on the mutation rate and spectrum of Hepatitis C virus in vivo. J Virol. 2009;83:5760–4. doi: 10.1128/JVI.00201-09. pmid:19321623
[54]
Ribeiro RM, Li H, Wang S, Stoddard MB, Learn GH, Korber BT, et al. Quantifying the diversification of hepatitis C virus (HCV) during primary infection: estimates of the in vivo mutation rate. PLoS Pathog. 2012;8:e1002881. doi: 10.1371/journal.ppat.1002881. pmid:22927817
[55]
Aaskov J, Buzacott K, Thu HM, Lowry K, Holmes EC. Long-term transmission of defective RNA viruses in humans and Aedes mosquitoes. Science. 2006;311:236–8. pmid:16410525 doi: 10.1126/science.1115030
[56]
Coiras M, López-Huertas MR, Pérez-Olmeda M, Alcamí J. Understanding HIV-1 latency provides clues for the eradication of long-term reservoirs. Nat Rev Microbiol. 2009;7:798–812. doi: 10.1038/nrmicro2223. pmid:19834480
[57]
Macallan DC, Asquith B, Irvine AJ, Wallace DL, Worth A, Ghattas H, et al. Measurement and modeling of human T cell kinetics. Eur J Immunol. 2003;33:2316–26. pmid:12884307 doi: 10.1002/eji.200323763
[58]
Koelsch KK, Liu L, Haubrich R, May S, Havlir D, Gunthard HF, et al. Dynamics of total, linear nonintegrated, and integrated HIV-1 DNA in vivo and in vitro. J Infect Dis. 2008;197:411–9. doi: 10.1086/525283. pmid:18248304
[59]
Murray JM, McBride K, Boesecke C, Bailey M, Amin J, Suzuki K, et al. Integrated HIV DNA accumulates prior to treatment while episomal HIV DNA records ongoing transmission afterwards. AIDS. 2012;26:543–50. doi: 10.1097/QAD.0b013e328350fb3c. pmid:22410637
[60]
Rihn SJ, Wilson SJ, Loman NJ, Alim M, Bakker SE, Bhella D, et al. Extreme genetic fragility of the HIV-1 capsid. PLoS Pathog. 2013;9:e1003461. doi: 10.1371/journal.ppat.1003461. pmid:23818857
[61]
Rihn SJ, Hughes J, Wilson SJ, Bieniasz PD. Uneven genetic robustness of HIV-1 integrase. J Virol. 2015;89:552–67. doi: 10.1128/JVI.02451-14. pmid:25339768
[62]
Ho YC, Shan L, Hosmane NN, Wang J, Laskey SB, Rosenbloom DI, et al. Replication-competent noninduced proviruses in the latent reservoir increase barrier to HIV-1 cure. Cell. 2013;155:540–51. doi: 10.1016/j.cell.2013.09.020. pmid:24243014
[63]
Bradwell K, Combe M, Domingo-Calap P, Sanjuán R. Correlation between mutation rate and genome size in riboviruses: mutation rate of bacteriophage Qbeta. Genetics. 2013;195:243–51. doi: 10.1534/genetics.113.154963. pmid:23852383
[64]
Fourati S, Malet I, Lambert S, Soulie C, Wirden M, Flandre P, et al. E138K and M184I mutations in HIV-1 reverse transcriptase coemerge as a result of APOBEC3 editing in the absence of drug exposure. AIDS. 2012;26:1619–24. doi: 10.1097/QAD.0b013e3283560703. pmid:22695298
[65]
Goetz MB, Leduc R, Kostman JR, Labriola AM, Lie Y, Weidler J, et al. Relationship between HIV coreceptor tropism and disease progression in persons with untreated chronic HIV infection. J Acquir Immune Defic Syndr. 2009;50:259–66. doi: 10.1097/QAI.0b013e3181989a8b. pmid:19194318
[66]
Poveda E, Briz V, Quinones-Mateu M, Soriano V. HIV tropism: diagnostic tools and implications for disease progression and treatment with entry inhibitors. AIDS. 2006;20:1359–67. pmid:16791010 doi: 10.1097/01.aids.0000233569.74769.69
[67]
Suspène R, Guetard D, Henry M, Sommer P, Wain-Hobson S, Vartanian JP. Extensive editing of both hepatitis B virus DNA strands by APOBEC3 cytidine deaminases in vitro and in vivo. Proc Natl Acad Sci USA. 2005;102:8321–6. pmid:15919829 doi: 10.1073/pnas.0408223102
[68]
Vartanian JP, Guetard D, Henry M, Wain-Hobson S. Evidence for editing of human papillomavirus DNA by APOBEC3 in benign and precancerous lesions. Science. 2008;320:230–3. doi: 10.1126/science.1153201. pmid:18403710
[69]
Suspène R, Aynaud MM, Koch S, Pasdeloup D, Labetoulle M, Gaertner B, et al. Genetic editing of herpes simplex virus 1 and Epstein-Barr herpesvirus genomes by human APOBEC3 cytidine deaminases in culture and in vivo. J Virol. 2011;85:7594–602. doi: 10.1128/JVI.00290-11. pmid:21632763
[70]
Cattaneo R, Schmid A, Eschle D, Baczko K, ter M, V, Billeter MA. Biased hypermutation and other genetic changes in defective measles viruses in human brain infections. Cell. 1988;55:255–65. pmid:3167982 doi: 10.1016/0092-8674(88)90048-7
[71]
Murphy DG, Dimock K, Kang CY. Numerous transitions in human parainfluenza virus 3 RNA recovered from persistently infected cells. Virology. 1991;181:760–3. pmid:1849685 doi: 10.1016/0042-6822(91)90913-v
[72]
Martínez I, Melero JA. A model for the generation of multiple A to G transitions in the human respiratory syncytial virus genome: predicted RNA secondary structures as substrates for adenosine deaminases that act on RNA. J Gen Virol. 2002;83:1445–55. pmid:12029160 doi: 10.1099/0022-1317-83-6-1445
[73]
Zahn RC, Schelp I, Utermohlen O, von LD. A-to-G hypermutation in the genome of lymphocytic choriomeningitis virus. J Virol. 2007;81:457–64. pmid:17020943 doi: 10.1128/jvi.00067-06
[74]
Suspène R, Renard M, Henry M, Guetard D, Puyraimond-Zemmour D, Billecocq A, et al. Inversing the natural hydrogen bonding rule to selectively amplify GC-rich ADAR-edited RNAs. Nucleic Acids Res. 2008;36:e72. doi: 10.1093/nar/gkn295. pmid:18515351
[75]
García-Merino I, de Las Cuevas N, Jiménez JL, Gallego J, Gómez C, Prieto C, et al. The Spanish HIV BioBank: a model of cooperative HIV research. Retrovirology. 2009;6:27–6. doi: 10.1186/1742-4690-6-27. pmid:19272145
[76]
Sandonís V, Casado C, Alvaro T, Pernas M, Olivares I, García S, et al. A combination of defective DNA and protective host factors are found in a set of HIV-1 ancestral LTNPs. Virology. 2009;391:73–82. doi: 10.1016/j.virol.2009.05.022. pmid:19559455
[77]
Schmieder R, Edwards R. Quality control and preprocessing of metagenomic datasets. Bioinformatics. 2011;27:863–4. doi: 10.1093/bioinformatics/btr026. pmid:21278185
[78]
Langmead B, Salzberg SL. Fast gapped-read alignment with Bowtie 2. Nat Methods. 2012;9:357–9. doi: 10.1038/nmeth.1923. pmid:22388286
[79]
Yang X, Charlebois P, Gnerre S, Coole MG, Lennon NJ, Levin JZ, et al. De novo assembly of highly diverse viral populations. BMC Genomics. 2012;13:475–13. doi: 10.1186/1471-2164-13-475. pmid:22974120
[80]
Lee WP, Stromberg MP, Ward A, Stewart C, Garrison EP, Marth GT. MOSAIK: a hash-based algorithm for accurate next-generation sequencing short-read mapping. PLoS ONE. 2014;9:e90581. doi: 10.1371/journal.pone.0090581. pmid:24599324
[81]
Henn MR, Boutwell CL, Charlebois P, Lennon NJ, Power KA, Macalalad AR, et al. Whole genome deep sequencing of HIV-1 reveals the impact of early minor variants upon immune recognition during acute infection. PLoS Pathog. 2012;8:e1002529. doi: 10.1371/journal.ppat.1002529. pmid:22412369
